Fig. 2From: Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilatorMean (SD) change from baseline in (a) heart rate and (b) QTcF at each timepoint over 12 h post-dose (safety population). bpm = beats per minute; QTcF = QT interval corrected for heart rate using the Fridericia formula; SD = standard deviationBack to article page